Crucially, oxaliplatin resistance in CRC cells was overcome by pharmacological inhibition of CDC7 with the CDC7 inhibitor XL413, which additionally avoided tumor ball formation, clone creation, and cell proliferation. This evidence concerns the gene CDC7 and neoplasm.